Abbott Laboratories (ABT) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Total Assets Chart for Abbott Laboratories

Abbott Laboratories (ABT) total assets for FY2025 were USD 86.7B, a 6.5% change from FY2024. Abbott Laboratories's total assets grew from USD 3.5B in 1985 to USD 86.7B in 2025 (2400.1% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of 7.0%, 20-year CAGR of 5.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$186.81B
Implied Share Price
$107.96
Enterprise Value
$209.91B
Revenue (TTM)
$46.58B
EBITDA
$11.68B
Profit Margin
11.65%
Trailing P/E
34.27
Forward P/E
19.16
Price/Book (MRQ)
3.58
Price/Sales (TTM)
4.04
EV/EBITDA
17.91
EV/Revenue
4.51
Dividend Yield
2.35%
Book Value
$29.54
Free Cash Flow (FY2025)
$7.39B
Free Cash Flow Yield
3.96%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.